오치우 박사, 황지은 학생, 박해나 박사, 김서영 학생의 “pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease” 논문이 Journal of Nanobiotechnology (IF: 12.6)에 게재되었다.

본 연구는 염증성 장질환(Inflammatory Bowel Disease, IBD)의 정밀 치료를 위해 pH-반응성 경구 리포좀 전달 시스템을 설계하고, hydrogen sulfide(H₂S) donor인 GYY4137을 담지하여 대장에서 선택적으로 약물이 방출되도록 구현하였다. 해당 플랫폼은 염증 부위에 약물을 국소적으로 전달함으로써 전신 부작용을 최소화하고, 염증 억제 및 장 조직 회복 효과를 검증하였다. 본 연구는 IBD 치료를 위한 경구 기반 나노의약 플랫폼의 가능성을 제시하며, 정밀 면역조절 치료 전략의 발전 방향을 제안한다.

Dr. Chiwoo Oh, Jee-Eun Hwang, Dr. Haena Park, and Seo-Young Kim have published their paper entitled “pH-responsive Oral Liposomal Delivery of Hydrogen Sulfide Donor GYY4137 Enables Colon-Targeted Therapy for Inflammatory Bowel Disease” in Journal of Nanobiotechnology (IF: 12.6).

This study presents a pH-responsive oral liposomal delivery system designed for the precision treatment of inflammatory bowel disease (IBD). The authors encapsulated the hydrogen sulfide (H₂S) donor GYY4137 into liposomes engineered to enable selective drug release in the colon in response to gastrointestinal pH changes. The platform achieves localized drug delivery to inflamed tissues while minimizing systemic side effects and demonstrates significant anti-inflammatory effects along with improved intestinal tissue recovery. These findings highlight the potential of oral nanomedicine-based platforms for IBD treatment and provide valuable direction for the development of precision immunomodulatory therapies.